Login to Your Account

Obesity Meeting 2010

Debating What's Needed for an Obesity Approval

By Trista Morrison

Monday, October 18, 2010
Obesity's "big three" are top of mind these days, thanks to recent FDA panel rejections and upcoming FDA decision dates for Arena Pharmaceuticals Inc.'s Lorqess (lorcaserin) and Vivus Inc.'s Qnexa (phentermine/topiramate), as well as a pending panel for Orexigen Therapeutics Inc.'s Contrave (naltrexone SR/bupropion SR).

To continue reading subscribe now to BioWorld Insight

Learn More about BioWorld Insight

Already a subscriber? Sign In or Buy now to activate your subscription